Inhibrx, Inc., a biotechnology company with four clinical programs in development and a strong emerging pipeline, announced that the European Commission ("EC"), based on...
Inhibrx, Inc., a biotechnology company with four clinical programs in development and a strong emerging pipeline, announced that the U.S. Food and Drug Administration,...
